{
    "nct_id": "NCT03117751",
    "official_title": "Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma",
    "inclusion_criteria": "* Diagnosis of B- or T-ALL or LLy by immunophenotyping:\n* LLy participants must have < 25% tumor cells in bone marrow and peripheral blood by morphology and flow cytometry. If any of these show â‰¥25% blasts, patient will be considered to have leukemia. Patients with MPAL are eligible.\n* Age 1-18 years (inclusive).\n* No prior therapy, or limited prior therapy, including systemic glucocorticoids for one week or less, one dose of vincristine, emergency radiation therapy (e.g., to the mediastinum, head and neck, orbit, etc.) and one dose of intrathecal chemotherapy.\n* Written, informed consent and assent following Institutional Review Board (IRB), National Cancer Institute (NCI), Food and Drug Administration (FDA), and Office of Human Research Protections (OHRP) Guidelines.\nHealthy volunteers allowed\nMust have minimum age of 1 Year\nMust have maximum age of 18 Years",
    "exclusion_criteria": "* Participants who are pregnant or lactating. Males or females of reproductive potential must agree to use effective contraception for the duration of study participation.\n* Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.",
    "miscellaneous_criteria": ""
}